… ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate … Ionis Pharmaceuticals ProQR receives exclusive worldwide license for IONIS-RHO-2.5 Rx , now QR-1123, for autosomal … the signing of an agreement with Ionis Pharmaceuticals to license QR-1123 (formerly “IONIS-RHO-2.5 Rx ”), an RNA …
… ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly Companies … N.V. (Nasdaq: PRQR) (ProQR), today announced a global licensing and research collaboration with Eli Lilly and …
Partnerships in our industry are very common as companies look to benefit from knowledge and resource sharing. In this blog we explore why companies, like ProQR, partner with other companies.
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
… assets. ProQR continues to execute on its global licensing and research partnership with Eli Lilly, focused on … Carreño was most recently Global Business Development & Licensing Head (BD&L) in the Ophthalmology franchise at …
… targets identified by Galapagos -- ProQR plans additional licensing, partnering and other strategic relationships for … and laboratory consumables, outsourced activities, license and intellectual property costs and other allocated …
… Eli Lilly and Company (Lilly) and ProQR entered into a licensing and research collaboration related to ProQR’s … payment of $20 million from Lilly related to the Axiomer licensing and research collaboration. Research and …
… these ProQR-owned patents, the Company has an exclusive license to U.S. patent no. 9,617,535 from Massachusetts … and create value for this novel technology through licensing, partnering and other strategic relationships. In …
